Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 69642-69643 [2012-28177]
Download as PDF
<![CDATA[
69642
Federal Register / Vol. 77, No. 224 / Tuesday, November 20, 2012 / Notices
Scientific Review, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, NIH, 6100 Executive
Blvd., Room 5B01, Rockville, MD 20852,
301–435–6973, David.Weinberg@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: November 14, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–28161 Filed 11–19–12; 8:45 am]
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
wreier-aviles on DSK5TPTVN1PROD with
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; ‘‘Biomedical/
Biobehavioral Research Administration
Development (BRAD) Award (G11).’’
Date: November 29, 2012.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Rockville, MD 20852
(Telephone Conference).
Contact Person: Anne Krey, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, Eunice Kennedy Shriver
National Institute of Child Health And
Human Development, NIH, 6100 Executive
Blvd., Room 5B01, Bethesda, MD 20892,
301–435–6908, ak41o@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
Jkt 229001
[FR Doc. 2012–28159 Filed 11–19–12; 8:45 am]
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
15:12 Nov 19, 2012
Dated: November 13, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
Substance Abuse and Mental Health
Services Administration
BILLING CODE 4140–01–P
VerDate Mar<15>2010
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
SUMMARY:
Mrs.
Giselle Hersh, Division of Workplace
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs’’, as amended in the
revisions listed above, requires strict
standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Instrumented Initial Testing Facilities
(IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln Ave.,
West Allis, WI 53227, 414–328–7840/800–
877–7016. (Formerly: Bayshore Clinical
Laboratory.)
ACM Medical Laboratory, Inc., 160 Elmgrove
Park, Rochester, NY 14624, 585–429–2264.
Advanced Toxicology Network, 3560 Air
Center Cove, Suite 101, Memphis, TN
38118, 901–794–5770/888–290–1150.
Aegis Analytical Laboratories, 345 Hill Ave.,
Nashville, TN 37210, 615–255–2400.
(Formerly: Aegis Sciences Corporation,
Aegis Analytical Laboratories, Inc.).
Alere Toxicology Services, 1111 Newton St.,
Gretna, LA 70053, 504–361–8989/800–
433–3823. (Formerly: Kroll Laboratory
Specialists, Inc., Laboratory Specialists,
Inc.)
Alere Toxicology Services, 450 Southlake
Blvd., Richmond, VA 23236, 804–378–
9130. (Formerly: Kroll Laboratory
Specialists, Inc., Scientific Testing
E:\FR\FM\20NON1.SGM
20NON1
wreier-aviles on DSK5TPTVN1PROD with
Federal Register / Vol. 77, No. 224 / Tuesday, November 20, 2012 / Notices
Laboratories, Inc.; Kroll Scientific Testing
Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock, AR
72209 –7056, 501–202–2783. (Formerly:
Forensic Toxicology Laboratory Baptist
Medical Center.)
Clinical Reference Lab, 8433 Quivira Road,
Lenexa, KS 66215–2802, 800–445–6917.
Doctors Laboratory, Inc., 2906 Julia Drive,
Valdosta, GA 31602, 229–671–2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns
Road, Warminster, PA 18974, 215–674–
9310.
ElSohly Laboratories, Inc., 5 Industrial Park
Drive, Oxford, MS 38655, 662–236–2609.
Gamma-Dynacare Medical Laboratories*, A
Division of the Gamma-Dynacare
Laboratory Partnership, 245 Pall Mall
Street, London, ONT, Canada N6A 1P4,
519–679–1630.
Laboratory Corporation of America Holdings,
7207 N. Gessner Road, Houston, TX 77040,
713–856–8288/800–800–2387.
Laboratory Corporation of America Holdings,
69 First Ave., Raritan, NJ 08869, 908–526–
2400/800–437–4986. (Formerly: Roche
Biomedical Laboratories, Inc.)
Laboratory Corporation of America Holdings,
1904 Alexander Drive, Research Triangle
Park, NC 27709, 919–572–6900/800–833–
3984. (Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of Roche
Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A Member
of the Roche Group.)
Laboratory Corporation of America Holdings,
1120 Main Street, Southaven, MS 38671,
866–827–8042/800–233–6339. (Formerly:
LabCorp Occupational Testing Services,
Inc.; MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics, 10101
Renner Blvd., Lenexa, KS 66219, 913–888–
3927/800–873–8845. (Formerly: Quest
Diagnostics Incorporated; LabOne, Inc.;
Center for Laboratory Services, a Division
of LabOne, Inc.)
Maxxam Analytics*, 6740 Campobello Road,
Mississauga, ON, Canada L5N 2L8, 905–
817–5700. (Formerly: Maxxam Analytics
Inc., NOVAMANN (Ontario), Inc.)
MedTox Laboratories, Inc., 402 W. County
Road D, St. Paul, MN 55112, 651–636–
7466/800–832–3244.
MetroLab-Legacy Laboratory Services, 1225
NE 2nd Ave., Portland, OR 97232, 503–
413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical Center,
Forensic Toxicology Laboratory, 1 Veterans
Drive, Minneapolis, MN 55417, 612–725–
2088.
National Toxicology Laboratories, Inc., 1100
California Ave., Bakersfield, CA 93304,
661–322–4250/800–350–3515.
One Source Toxicology Laboratory, Inc., 1213
Genoa-Red Bluff, Pasadena, TX 77504,
888–747–3774. (Formerly: University of
Texas Medical Branch, Clinical Chemistry
Division; UTMB Pathology-Toxicology
Laboratory.)
Pacific Toxicology Laboratories, 9348 DeSoto
Ave., Chatsworth, CA 91311, 800–328–
6942. (Formerly: Centinela Hospital
Airport Toxicology Laboratory.)
VerDate Mar<15>2010
15:12 Nov 19, 2012
Jkt 229001
Pathology Associates Medical Laboratories,
110 West Cliff Dr., Spokane, WA 99204,
509–755–8991/800–541–7891 x7.
Phamatech, Inc., 10151 Barnes Canyon Road,
San Diego, CA 92121, 858–643–5555.
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084, 800–
729–6432. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories.)
Quest Diagnostics Incorporated, 400 Egypt
Road, Norristown, PA 19403, 610–631–
4600/877–642–2216. (Formerly:
SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304, 818–
737–6370. (Formerly: SmithKline Beecham
Clinical Laboratories.)
Redwood Toxicology Laboratory, 3650
Westwind Blvd., Santa Rosa, CA 95403,
707–570–4434.
South Bend Medical Foundation, Inc., 530 N.
Lafayette Blvd., South Bend, IN 46601,
574–234–4176 x1276.
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix, AZ
85040, 602–438–8507/800–279–0027.
STERLING Reference Laboratories, 2617 East
L Street, Tacoma, Washington 98421, 800–
442–0438.
Toxicology & Drug Monitoring Laboratory,
University of Missouri Hospital & Clinics,
301 Business Loop 70 West, Suite 208,
Columbia, MO 65203, 573–882–1273.
US Army Forensic Toxicology Drug Testing
Laboratory, 2490 Wilson St., Fort George G.
Meade, MD 20755–5235, 301–677–7085.
*The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 30, 2010 (75 FR
22809). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
69643
the NLCP certification maintenance
program.
Janine Denis Cook,
Chemist, Division of Workplace Programs,
Center for Substance Abuse Prevention,
SAMHSA.
[FR Doc. 2012–28177 Filed 11–19–12; 8:45 am]
BILLING CODE 4160–20–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–3349–
EM; Docket ID FEMA–2011–0001]
Maryland; Emergency and Related
Determinations
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
This is a notice of the
Presidential declaration of an
emergency for the State of Maryland
(FEMA–3349–EM), dated October 28,
2012, and related determinations.
DATES: Effective Date: October 28, 2012.
FOR FURTHER INFORMATION CONTACT:
Peggy Miller, Office of Response and
Recovery, Federal Emergency
Management Agency, 500 C Street SW.,
Washington, DC 20472, (202) 646–3886.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that, in a letter dated
October 28, 2012, the President issued
an emergency declaration under the
authority of the Robert T. Stafford
Disaster Relief and Emergency
Assistance Act, 42 U.S.C. 5121–5207
(the Stafford Act), as follows:
SUMMARY:
I have determined that the emergency
conditions in the State of Maryland resulting
from Hurricane Sandy beginning on October
26, 2012, and continuing, are of sufficient
severity and magnitude to warrant an
emergency declaration under the Robert T.
Stafford Disaster Relief and Emergency
Assistance Act, 42 U.S.C. 5121 et seq. (‘‘the
Stafford Act’’). Therefore, I declare that such
an emergency exists in the State of Maryland.
You are authorized to provide appropriate
assistance for required emergency measures,
authorized under Title V of the Stafford Act,
to save lives and to protect property and
public health and safety, and to lessen or
avert the threat of a catastrophe in the
designated areas. Specifically, you are
authorized to provide assistance for
emergency protective measures (Category B),
limited to direct Federal assistance, under
the Public Assistance program.
Consistent with the requirement that
Federal assistance is supplemental, any
Federal funds provided under the Stafford
Act for Public Assistance will be limited to
75 percent of the total eligible costs. In order
E:\FR\FM\20NON1.SGM
20NON1
]]>Agencies
[Federal Register Volume 77, Number 224 (Tuesday, November 20, 2012)]
[Notices]
[Pages 69642-69643]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-28177]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of Laboratories and Instrumented Initial Testing
Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing
for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the Laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory Guidelines were first published
in the Federal Register on April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal Register on June 9, 1994 (59 FR
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and
on April 30, 2010 (75 FR 22809).
A notice listing all currently certified Laboratories and
Instrumented Initial Testing Facilities (IITF) is published in the
Federal Register during the first week of each month. If any
Laboratory/IITF's certification is suspended or revoked, the
Laboratory/IITF will be omitted from subsequent lists until such time
as it is restored to full certification under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of
Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially
developed in accordance with Executive Order 12564 and section 503 of
Public Law 100-71. The ``Mandatory Guidelines for Federal Workplace
Drug Testing Programs'', as amended in the revisions listed above,
requires strict standards that Laboratories and Instrumented Initial
Testing Facilities (IITF) must meet in order to conduct drug and
specimen validity tests on urine specimens for Federal agencies.
To become certified, an applicant Laboratory/IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a Laboratory/IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and Instrumented Initial Testing Facilities (IITF) in
the applicant stage of certification are not to be considered as
meeting the minimum requirements described in the HHS Mandatory
Guidelines. A Laboratory/IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the minimum standards to conduct drug
and specimen validity tests on urine specimens:
Instrumented Initial Testing Facilities (IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840/800-877-7016. (Formerly: Bayshore Clinical Laboratory.)
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY
14624, 585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101,
Memphis, TN 38118, 901-794-5770/888-290-1150.
Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210,
615-255-2400. (Formerly: Aegis Sciences Corporation, Aegis
Analytical Laboratories, Inc.).
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-
361-8989/800-433-3823. (Formerly: Kroll Laboratory Specialists,
Inc., Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130. (Formerly: Kroll Laboratory Specialists, Inc.,
Scientific Testing
[[Page 69643]]
Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.)
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little
Rock, AR 72209 -7056, 501-202-2783. (Formerly: Forensic Toxicology
Laboratory Baptist Medical Center.)
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802,
800-445-6917.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA
18974, 215-674-9310.
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS
38655, 662-236-2609.
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT,
Canada N6A 1P4, 519-679-1630.
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan,
NJ 08869, 908-526-2400/800-437-4986. (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984.
(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A
Member of the Roche Group.)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339. (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center.)
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845. (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a
Division of LabOne, Inc.)
Maxxam Analytics*, 6740 Campobello Road, Mississauga, ON, Canada L5N
2L8, 905-817-5700. (Formerly: Maxxam Analytics Inc., NOVAMANN
(Ontario), Inc.)
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244.
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff,
Pasadena, TX 77504, 888-747-3774. (Formerly: University of Texas
Medical Branch, Clinical Chemistry Division; UTMB Pathology-
Toxicology Laboratory.)
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942. (Formerly: Centinela Hospital Airport
Toxicology Laboratory.)
Pathology Associates Medical Laboratories, 110 West Cliff Dr.,
Spokane, WA 99204, 509-755-8991/800-541-7891 x7.
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858-
643-5555.
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA
30084, 800-729-6432. (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA
19403, 610-631-4600/877-642-2216. (Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-Science Laboratories.)
Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA
91304, 818-737-6370. (Formerly: SmithKline Beecham Clinical
Laboratories.)
Redwood Toxicology Laboratory, 3650 Westwind Blvd., Santa Rosa, CA
95403, 707-570-4434.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South
Bend, IN 46601, 574-234-4176 x1276.
Southwest Laboratories, 4625 E. Cotton Center Boulevard, Suite 177,
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
STERLING Reference Laboratories, 2617 East L Street, Tacoma,
Washington 98421, 800-442-0438.
Toxicology & Drug Monitoring Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia,
MO 65203, 573-882-1273.
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson
St., Fort George G. Meade, MD 20755-5235, 301-677-7085.
*The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 30, 2010 (75 FR 22809).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Janine Denis Cook,
Chemist, Division of Workplace Programs, Center for Substance Abuse
Prevention, SAMHSA.
[FR Doc. 2012-28177 Filed 11-19-12; 8:45 am]
BILLING CODE 4160-20-P
